Re-purposing a cancer therapeutic in combination with a non-steroidal inflammatory drug for the treatment of Respiratory Syncytial Virus

Respiratory Syncytial Virus (RSV) is the major pathogen responsible for lower respiratory tract infections (LRTI) in young children, the immunosuppressed, and the elderly. RSV disease and pathology is by direct replication of the virus as well as the host inflammatory response to the virus. We propose to re-purpose a cancer therapeutic in association with a non-steroidal inflammatory drug for the treatment of RSV infections and reduction of RSV related host immune response (inflammation).